SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Lamberts Maximum Strength Milk Thistle Tablets Natures Best Maximum Strength Milk Thistle Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 300mg of standardised extract (as dry extract) from Milk Thistle fruits (Silybum marianum (L.) Gaertner) (equivalent to 7200mg- 8100mg of Milk Thistle fruits) corresponding to 174mg of Silymarin, calculated as silibinin.

Extraction solvent: Acetone 95% v/v

For full list of excipients, see section 6.1.

3    PHARMACEUTICAL FORM

Green coated large oval shaped tablets.

The inner core of the tablet has yellow/beige speckles.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

A traditional herbal medicinal product used to relieve the symptoms associated with occasional over indulgence of food and drink such as indigestion and upset stomach based on traditional use only.

4.2 Posology and method of administration

For oral administration

Adult and the elderly: the recommended dosage is 1 or 2 tablets daily.

This product is not recommended for children or adolescents under 18 years of age (See Section 4.4 special warnings and precautions for use)

If symptoms worsen during the use of the product or persist, a doctor or a qualified healthcare practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to Milk Thistle or plants of the Asteraceae/ Compositae family or to any of the excipients.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

Patients suffering from active liver disease should consult their doctor before taking this product.

Milk Thistle may alter the way that certain drugs are broken down by the liver (see section 4.5 ‘Interaction with other medicinal products and other forms of interaction’)

If the symptoms worsen during the use of the product or if symptoms persist, consult a doctor or qualified healthcare practitioner.

The use of this product in children and adolescents under 18 years of age is not recommended as there is no relevant indication.

4.5 Interaction with other medicinal products and other forms of interaction

In vitro Milk Thistle extract resulted in inhibition of CYP isoenzymes. However the clinical relevance of these findings is not established.

4.6 Fertility, pregnancy and lactation

The safety of this product during pregnancy has not been established. In the absence of sufficient data the use in pregnancy and lactation is not recommended.

Tests on the effects on fertility have not been performed

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

Gastrointestinal reactions (nausea, upset stomach, diarrhoea). Headache, allergic reactions (urticaria, skin rash, pruritis, analphylaxis)

The frequency is not known

If other adverse reactions not mentioned above occur, a doctor or qualified healthcare practitioner should be consulted.

4.9 Overdose

No case of overdose has been reported.

Supportive and symptomatic treatment should be provided as appropriate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2 Pharmacokinetic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3 Preclinical safety data

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Tablet Core Maltodextrin

Microcrystalline Cellulose Sodium Croscarmellose Stearic Acid Magnesium Stearate

Colloidal Hydrated Silica

Tablet Coating Hypromellose HPMC Polydextrose Titanium Dioxide Curcumin

Copper Chlorophyllin Medium Chain Triglycerides

6.2 Incompatibilities

Not Applicable

6.3 Shelf life

2 years

6.4    Special precautions for storage

Do not store above 25 °C. Store in the original packaging

6.5    Nature and contents of container

Tablets are packed into PVC/PVDC blister strips of 15 tablets in the following pack sizes; 30, 60, 90 Tablets and packed into a Carton.

Not all pack sizes may be marketed

6.6    Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

LAMBERTS HEALTHCARE LIMITED 1 LAMBERTS ROAD TUNBRIDGE WELLS KENT TN2 3EH

8    MARKETING AUTHORISATION NUMBER(S)

THR 34425/0010

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

18/11/2013

10    DATE OF REVISION OF THE TEXT

30/07/2014